We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Corcept Therapeutics (CORT) Up 6.6% Since Earnings Report: Can It Continue?
Read MoreHide Full Article
A month has gone by since the last earnings report for Corcept Therapeutics Incorporated (CORT - Free Report) . Shares have added about 6.6% in that time frame.
Will the recent positive trend continue leading up to its next earnings release, or is CORT due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Corcept's Earnings and Sales Beat Estimates in Q1
Corcept’s adjusted first-quarter 2018 earnings of 19 cents per share beat the Zacks Consensus Estimate by a penny. The reported figure improved from the year-ago adjusted earnings of 6 cents.
Revenues increased 109% from the year-ago quarter to $57.7 million and beat the Zacks Consensus Estimate of $56 million.
Research and development expenses improved 124.2% to $1.5 million. Likewise, selling, general and administrative expenses were up 70.4% to $3.5 million. In fact, the increase in operating expenses can be attributed to higher spending on the development of relacorilant, CORT118335 and CORT125281 and costs arising from increased sales volume.
Pipeline Update
The company completed enrollment in phase II study of relacorilant to treat patients with Cushing’s syndrome and full datais expected in third quarter of 2018.
Relacorilant generated encouraging early data as a potential treatment for solid tumors. The company will present data from the dose-finding portion of its Phase !/II study of relacorilant combined with Abraxane at the ASCO annual meeting in June 2018.
The company is enrolling patients in its dose- ranging study of CORT125281 in combination with Xtandi to treat metastatic castration-resistant prostate cancer at sites in the United States and Europe.
The company’s lead compound for metabolic disorders, CORT118335, continues to progress in its phase I study. The company is planning for phase II studies in patients with antipsychotic-induced weight gain and non-alcoholic steatohepatitis by end of 2018.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates. There have been two revisions lower for the current quarter.
Corcept Therapeutics Incorporated Price and Consensus
At this time, CORT has a strong Growth Score of A, though it is lagging a lot on the momentum front with a D. The stock was also allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
The company's stock is suitable solely for growth based on our styles scores.
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift. Notably, CORT has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Corcept Therapeutics (CORT) Up 6.6% Since Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Corcept Therapeutics Incorporated (CORT - Free Report) . Shares have added about 6.6% in that time frame.
Will the recent positive trend continue leading up to its next earnings release, or is CORT due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Corcept's Earnings and Sales Beat Estimates in Q1
Corcept’s adjusted first-quarter 2018 earnings of 19 cents per share beat the Zacks Consensus Estimate by a penny. The reported figure improved from the year-ago adjusted earnings of 6 cents.
Revenues increased 109% from the year-ago quarter to $57.7 million and beat the Zacks Consensus Estimate of $56 million.
Research and development expenses improved 124.2% to $1.5 million. Likewise, selling, general and administrative expenses were up 70.4% to $3.5 million. In fact, the increase in operating expenses can be attributed to higher spending on the development of relacorilant, CORT118335 and CORT125281 and costs arising from increased sales volume.
Pipeline Update
The company completed enrollment in phase II study of relacorilant to treat patients with Cushing’s syndrome and full datais expected in third quarter of 2018.
Relacorilant generated encouraging early data as a potential treatment for solid tumors. The company will present data from the dose-finding portion of its Phase !/II study of relacorilant combined with Abraxane at the ASCO annual meeting in June 2018.
The company is enrolling patients in its dose- ranging study of CORT125281 in combination with Xtandi to treat metastatic castration-resistant prostate cancer at sites in the United States and Europe.
The company’s lead compound for metabolic disorders, CORT118335, continues to progress in its phase I study. The company is planning for phase II studies in patients with antipsychotic-induced weight gain and non-alcoholic steatohepatitis by end of 2018.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates. There have been two revisions lower for the current quarter.
Corcept Therapeutics Incorporated Price and Consensus
Corcept Therapeutics Incorporated Price and Consensus | Corcept Therapeutics Incorporated Quote
VGM Scores
At this time, CORT has a strong Growth Score of A, though it is lagging a lot on the momentum front with a D. The stock was also allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
The company's stock is suitable solely for growth based on our styles scores.
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift. Notably, CORT has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.